Latest news with #TevaPharmaceuticalIndustriesLtd.
Yahoo
09-05-2025
- Business
- Yahoo
Generic Drugs Market size is projected to reach USD 594.99 billion by 2031, With growing at a CAGR of 5.0%
The report runs an in-depth analysis of market trends, key players, and future opportunities. The generic drugs market comprises a range of drugs used for the treatment of various conditions that are expected to register strength in the coming years. US & Canada, May 09, 2025 (GLOBE NEWSWIRE) -- According to a new comprehensive report from The Insight Partners, the global Generic Drugs Market is growing owing to patent expiry and loss of market exclusivity, along with increasing government initiatives to promote the use of generic drugs. The global generic drugs market Key players include Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy's Laboratories Ltd., Novartis Pharmaceuticals Corporation, Apotex Inc., Pfizer Inc. are significant contributors to the U.S. generics market, supplying nearly half of the nation's generic prescriptions. The oncology segment is expected to witness notable growth during the forecast period. To explore the valuable insights in the Generic Drugs Market report, you can easily download a sample PDF of the report - Overview of Report Findings 1. Market Growth: The generic drugs market is expected to reach US$ 594.99 Billion by 2031 from US$ 423.55 billion in 2023 at a CAGR of 5.0% during the forecast period. Generic Drugs have the same active ingredients as the branded drugs with different excipients which drastically reduces the prices of drugs and makes it affordable to large population with the same efficacy, intended use and performance. The increasing prevalence of various diseases, increasing patent expiry, and market exclusivity, along with higher affordability of generic drugs, are major factors driving the market growth. Additionally, supportive government and regulatory policies further contribute to the market growth. 2. Patent Expiry and Loss of Market Exclusivity: When patents expire, generic manufacturers can produce and sell bioequivalent versions of these drugs at lower prices, unlocking new market opportunities. In 2025-2026, Keytruda (Merck's cancer immunotherapy), which generated over US$ 25 billion in 2024 sales, and Ozempic (Novo Nordisk's treatment for diabetes and obesity) are set to lose their patents. Additionally, other high-revenue drugs, such as Eliquis (Bristol-Myers Squibb's blood thinner) and Cosentyx (Novartis' immunology drug), are also expected to experience patent loss, paving the way for more generic pharmaceuticals and biosimilars. In 2024, several blockbuster drugs lost their patents, creating additional space for generic alternatives. Notable drugs facing patent expiration include: Abilify Maintaina (Otsuka Pharmaceutical), an injectable antipsychotic that generated US$ 15.5 billion in sales in 2022, lost its patent in October 2024. Xarelto (Janssen Pharmaceuticals), an anticoagulant, lost its patent in August 2024. Farxiga (AstraZeneca), an anti-diabetic drug with annual sales of approximately US$ 4.3 billion, lost its patent in 2024. Lynparza (AstraZeneca), a cancer treatment generating ~US$ 2.7 billion in sales, lost its patent in 2024. Symbicort (AstraZeneca), a respiratory drug, lost its patent in November 2024. Entresto (Novartis), a heart failure treatment generating US$ 2.5 billion in sales in 2022, lost its patent. Latuda (Sunovion Pharmaceuticals), an antipsychotic with US$ 1.8 billion in sales, lost its patent in February 2024. Xifaxan (Salix Pharmaceuticals), a gastrointestinal drug with sales of US$ 1.6 billion, lost its patent in June 2024. Cabometyx (Exelixis), used to treat advanced renal cell carcinoma, lost its patent in September 2024. These drugs have generated substantial global revenue and opened opportunities for generic manufacturers to create cost-effective alternatives. Between 2023 and 2029, patents for more than 100 critical drugs—including those for cancer, diabetes, and cardiovascular diseases—are set to expire, representing over US$ 300 billion in global annual sales. Thus, the loss of exclusivity is increasing the production of generics and biosimilars, leading to a reduction in global healthcare costs. 3. Government Initiatives Promoting the Use of Generic Drugs: In high-income countries, governments are recognizing the financial benefits associated with the use of generics, which help in the overall reduction of healthcare spending. These initiatives offer financial benefits to healthcare providers who prescribe generic alternatives instead of brand-name drugs, with programs such as subsidies, tax rebates, or bonuses based on the volume of generics prescribed. In the US, Medicare and Medicaid promote the use of generics so they gain acceptance in public healthcare systems. Germany and France have implemented stringent regulations that mandate pharmacists to sell the generic version unless the prescription specifically states the brand-name alternative. Governments in India and Brazil are coming up with initiatives to help reduce increasing health costs and, thus, encourage the use of generics. In India, the Jan Aushadhi Scheme was initiated, which provides affordable generic medicines through public outlets, contributing to healthcare accessibility to millions. These efforts are not confined to developed economies but extend to economies with limited healthcare budgets, where cost-saving measures ensure access to medications. Thus, increasing demand for affordable drugs presents significant opportunites for pharmaceutical companies operating the generic drugs market. 4. Geographical Insights: In 2023, North America led the market with a substantial revenue share, followed by Europe and APAC. Asia Pacific is expected to register the highest CAGR during the forecast period. Stay Updated on The Latest Generic Drugs Market Trends: Market Segmentation Based on molecule type, the generic drugs market is segmented into antidepressants, antihistamines, analgesics, antibiotics, antivirals, diuretics, and others. The antibiotics segment held the largest share of the market in 2024. By indication, the generic drugs market is segmented into metabolic diseases, cancer, immunology, respiratory disorder, cardiovascular disorder, neurology disorder, rare disease, and others. The cancer segment held the largest share of the market in 2024. In terms of type, the generic drugs market is bifurcated into prescription and OTC drugs. The prescription segment held a larger share of the market in 2024. By distribution channel, the generic drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest share of the generic drugs market in 2024. The generic drugs market is segmented into five major regions: North America, Europe, APAC, Middle East & Africa, and South & Central America. Competitive Strategy and Development Key Players: Major companies operating in the generic drugs market include Novartis AG, F. Hoffmann-La Roche Ltd, GSK Plc, Johnson & Johnson, Merck KGaA, Pfizer Inc, Sanofi SA, AstraZeneca Plc, Eli Lilly and Co, Bristol-Myers Squibb Co, Teva Pharmaceutical Industries Ltd, Mylan NV, UCB SA, Becton Dickinson and Co, ESTEVE, and Hikma Pharmaceuticals Plc. Trending Topics: Pharmaceutical Market, Oncology Drugs Market, Antibiotics Market, OTC Drugs Market, Prescription Drugs Market, etc. Global Headlines on Generic Drugs Glenmark Launches Generic Ophthalmic Solution in US Market" Teva Announces the Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the US " Senores to Acquire Generic Drug from Dr. Reddy's " Synthon, a Global Leader in Complex Generic Drug Development and Manufacturing, Announces Investment from Goldman Sachs Alternatives "Purchase Premium Copy of Global Generic Drugs Market Size and Growth Report (2025-2031) at: The generic drugs market is growing owing to patent expirations, government policies, and the increasing demand for affordable medicines. The increasing patent expiry for cancer drugs, anti-diabetic drugs, and treatments in immunology has created opportunities for generic drug manufacturers to provide inexpensive alternatives. The entry of these generics is crucial in lowering healthcare expenditures across nations and providing easier access to therapies for patients, especially when the country's healthcare system has a constrained budget. Although financial incentives to healthcare providers and regulatory approaches to allow easier access to generics stimulate the trend, initiatives in advanced economies such as the US and Europe, as well as emerging markets such as India and Brazil, are making generics more available and affordable. The rise of generics is helpful in public healthcare systems that have limited budgets, where such savings ensure that greater numbers of people have access to needed treatments. The report from The Insight Partners, therefore, provides several stakeholders—including pharmaceutical manufacturers, Contract Research and Manufacturing Organizations, healthcare providers, biopharmaceutical manufacturers, and others—with valuable insights into how to successfully navigate this evolving market landscape and unlock new any Query Talk to Us Directly: Related Reports: Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us: If you have any queries about this report or if you would like further information, please contact us: Contact Person: Ankit Mathur E-mail: Phone: +1-646-491-9876 Home - while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
22-02-2025
- Health
- Yahoo
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn's disease
ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn's disease New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different doses New endpoints presented include findings on clinical and endoscopic outcomes and histological-endoscopic mucosal improvement Findings to form the basis for a phase 3 program, anticipated to start in H2 2025 Paris and Parsippany, NJ, February 22, 2025. Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today presented new, detailed results from the RELIEVE UCCD phase 2b study of duvakitug, a human IgG1-λ2 monoclonal antibody targeting TL1A, in patients with moderate-to-severe ulcerative colitis (UC) and Crohn's disease (CD), the two most common forms of inflammatory bowel disease (IBD). These results were shared in two oral presentations at the 20th Congress of the European Crohn's and Colitis Organisation (ECCO) in Berlin, Germany. Ulcerative colitis In the UC cohort of the RELIEVE UCCD study, 36% (450 mg dose) and 48% (900 mg dose) of patients treated with duvakitug achieved the primary endpoint of clinical remission (mMS)* at week 14 compared to 20% treated with placebo; placebo-adjusted rates were 16% (450 mg dose) and 27% (900 mg dose) (p=0.050 and 0.003, respectively). In addition, higher clinical remission rates were observed for both doses of duvakitug versus placebo in both advanced therapy (AT) -experienced and AT-naïve subgroups of patients. AT-experienced: 29% (450 mg) and 36% (900 mg), with placebo-adjusted rates of 22% (450 mg) and 29% (900 mg). AT-naïve: 39% (450 mg) and 53% (900 mg), with placebo-adjusted rates of 12% (450 mg) and 26% (900 mg). Additional endpoints observed*: Clinical response (mMS): 81% (450 mg) and 70% (900 mg) compared to 52% treated with placebo. Endoscopic improvement (MES): 45% (450 mg) and 50% (900 mg) compared to 23% treated with placebo. Histological-endoscopic mucosal improvement (HEMI): 30% (450 mg) and 33% (900 mg) compared to 16% treated with placebo. Medical University of Vienna, and lead investigator of the RELIEVE UCCD study 'Patients, many of whom have spent years in a recurring cycle of remission and relapse, have been waiting a long time for better options in treating ulcerative colitis. We're highly encouraged by the significant treatment response, compared to placebo, seen in the study, both in advanced therapy naïve-and experienced patients,' said Walter Reinisch, MD, PhD, Medical University of Vienna, and lead investigator of the RELIEVE UCCD study. 'With this potential of duvakitug to reduce inflammation, we could truly transform treatment for patients with IBD in a safe manner.' Crohn's diseaseIn the CD cohort of the RELIEVE UCCD study, 26% (450 mg dose) and 48% (900 mg dose) of patients treated with duvakitug achieved the primary endpoint of endoscopic response (SES-CD)* compared to 13% on placebo; placebo-adjusted rates were 13% (450 mg dose) and 35% (900 mg dose) at week 14 (p= 0.058 and <0.001, respectively). In addition, higher endoscopic response rates were observed for both doses of duvakitug versus placebo in both AT-experienced and AT-naïve subgroups of patients. AT-experienced: 11% (450 mg) and 48% (900 mg), with placebo-adjusted rates of 7% (450 mg) and 44% (900 mg). AT-naïve: 47% (450 mg) and 47% (900 mg), with placebo-adjusted rates of 25% (450 mg) and 25% (900 mg). Additional endpoints observed*: Endoscopic remission (SES-CD): 17% (450 mg) and 26% (900 mg) compared to 9% treated with placebo. Clinical remission (CDAI): 50% (450 mg) and 54% (900 mg) compared to 41% treated with placebo. Clinical response (CDAI): 61% (450 mg) and 62% (900 mg) compared to 41% treated with placebo. Clinical response (PRO2): 50% (450 mg) and 53% (900 mg) compared to 29% treated with placebo. Professor of Medicine in the Departments of Medicine, Epidemiology and Biostatistics at Western University, and lead investigator of the RELIEVE UCCD study 'Every day, I see patients with Crohn's disease who continue to suffer from the often-severe symptoms of the disease despite available treatments,' said Vipul Jairath, MBChB, DPhil, FRCP, FRCPC, Professor of Medicine in the Departments of Medicine, Epidemiology and Biostatistics at Western University, and lead investigator of the RELIEVE UCCD study. 'The endoscopic response rates seen in this study support the potential of duvakitug as an effective new option for those who are in desperate need of relief.' RELIEVE UCCD safety data summaryIn both the UC and CD cohorts, duvakitug was generally well tolerated with no emergent safety signals observed. No dose-dependent or adverse event (AE) pattern was observed for treatment-related AEs, serious adverse events (SAEs), AEs leading to discontinuation or adverse events of special interest (AESIs). Duvakitug is currently under clinical investigation, and its efficacy and safety have not been evaluated by any regulatory authority. About inflammatory bowel disease UC and CD, the two main types of IBD, are chronic inflammatory conditions of the gastrointestinal (GI) tract resulting in debilitating and persistent symptoms such as abdominal pain, diarrhea, rectal bleeding, fatigue and weight loss. Prolonged inflammation can lead to damage within the GI tract, including fibrosis, a common complication of IBD characterized by an accumulation of scar tissue in the intestinal wall, which may cause narrowing and obstruction often requiring hospitalization and surgery. There is currently no cure for IBD – the goal of treatment is to induce and maintain remission and prevent flares. About the RELIEVE UCCD phase 2b studyRELIEVE UCCD was a 14-week phase 2b, randomized, double-blinded, dose-ranging study to determine the efficacy, safety, pharmacokinetics, and tolerability of duvakitug in adults with moderate-to-severe UC or CD. The study was an innovative and efficient basket study design allowing the inclusion of patients with either type UC and CD. It is also the first and only randomized, blinded and placebo-controlled phase 2 study to investigate the impact of TL1A in CD. In the study, patients who met pre-specified inclusion criteria were randomized to receive one of two duvakitug doses or placebo, administered every two weeks subcutaneously, in a 1:1:1 ratio for each indication (UC or CD) stratified by previous exposure to advanced IBD therapies for 14 weeks. The UC cohort comprised adults with moderately to severely active disease with inadequate response, loss of response or intolerance to previous conventional and/or advanced therapies (AT). The CD cohort comprised adults with moderately to severely active disease with documented inadequate response, loss of response or intolerance to conventional and/or ATs. Primary efficacy endpoints are the number of participants who showed clinical remission (as defined by the modified Mayo score) in the UC cohort or the number of participants who showed endoscopic response (as defined by the SES-CD endoscopic score for CD) in the CD cohort. The study included sites in the US, Europe, Israel, and Asia. About duvakitugDuvakitug is a potential best-in-class human IgG1-λ2 monoclonal antibody that targets tumor necrosis factor (TNF)-like ligand 1A (TL1A), also known as TNF superfamily member 15 (TNFSF15). TL1A signaling is believed to amplify inflammation and drive fibrosis associated with IBD through binding its receptor, death receptor 3 (DR3). Duvakitug is uniquely designed to inhibit preferentially TL1A signaling via DR3, with the potential advantage of reduced TL1A-DcR3 inhibition. Duvakitug is currently in a phase 2b clinical study for the treatment of UC and CD, the two most common types of IBD. The safety and efficacy of duvakitug have not been reviewed by any regulatory authority. About the Teva and Sanofi collaborationTeva and Sanofi are collaborating to co-develop and co-commercialize Teva's duvakitug for the treatment of UC and CD. Each company will equally share the development costs globally, and the net profits and losses in major markets, with other markets subject to a royalty arrangement. Sanofi will lead the phase 3 clinical development program. Teva will lead commercialization of the product in Europe, Israel and specified other countries, and Sanofi will lead commercialization in North America, Japan, other parts of Asia and the rest of the world. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global pharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company's global network of capabilities enables its 37,000 employees across 57 markets to advance health by developing medicines for the future while championing the production of generics and biologics. If patients have a need, we're already working to address it. To learn more about how Teva is all in for better health, visit About Sanofi We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | Evan Berland | +1 215 432 0234 | Nicolas Obrist | +33 6 77 21 27 55 | Léo Le Bourhis | +33 6 75 06 43 81 | Victor Rouault | +33 6 70 93 71 40 | Gilbert | +1 516 521 2929 | Investor RelationsThomas Kudsk Larsen |+44 7545 513 693 | Alizé Kaisserian | +33 6 47 04 12 11 | Lauscher | +1 908 612 7239 | Keita Browne | +1 781 249 1766 | Pham | +33 7 85 93 30 17 | Elgoutni | + 1 617 710 3587 | Thibaud Châtelet | + 33 6 80 80 89 90 | Teva Media Relations TevaCommunicationsNorthAmerica@ Teva Investor Relations TevaIR@ Sanofi forward-looking statement This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi group. Teva Cautionary note regarding forward-looking statementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as 'should,' 'expect,' 'anticipate,' 'estimate,' 'target,' 'may,' 'project,' 'guidance,' 'intend,' 'plan,' 'believe' and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop duvakitug for the treatment of ulcerative colitis (UC) and Crohn's disease (CD); our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generic medicines; the effectiveness of our patents and other measures to protect our intellectual property rights; and other factors discussed in our Quarterly Report on Form 10-Q for the third quarter of 2024, and in our Annual Report on Form 10-K for the year ended December 31, 2023, including in the section captioned 'Risk Factors.' Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. *P-values reported are one-sided at a significance level of 0.10. mMS = modified Mayo Score; MES = Mayo Endoscopic Subscore; HEMI = Histological-Endoscopic Mucosal Improvement; SES-CD = Simple Endoscopic Score for Crohn's Disease; CDAI = Crohn's Disease Activity Index; PRO2 = 2-item Patient-Reported Outcome _____________________Attachment Press Release
